Raphael Onuku

Mr. Raphael Onuku

College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA
orcid
MedChem PhD Candidate, Taiwan’s MOE Outstanding Grad.

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2022 in Phytomedicine
Verified
Journal Article
Open access
RSRajeev K. Singla
Rajeev K. Singla
RDRonita De
Ronita De
Thomas EfferthThomas Efferth
Thomas Efferth
BMBruno Mezzetti
Bruno Mezzetti
SUSahab Uddin
Sahab Uddin
BSBairong Shen
Bairong Shen
The development of digital technologies and the evolution of open innovation approaches have enabled the creation of diverse virtual organizations and enterprises coordinating their activities primarily online. The open innovation platform titled "International Natural Product Sciences Taskforce" (INPST) was established in 2018, to bring together in collaborative environment individuals and organizations interested in natural product scientific research, and to empower their interactions by using digital communication tools. In this work, we present a general overview of INPST activities and showcase the specific use of Twitter as a powerful networking tool that was used to host a one-week "2021 INPST Twitter Networking Event" (spanning from 31st May 2021 to 6th June 2021) based on the application of the Twitter hashtag #INPST. The use of this hashtag during the networking event period was analyzed with Symplur Signals (https://www.symplur.com/), revealing a total of 6,036 tweets, shared by 686 users, which generated a total of 65,004,773 impressions (views of the respective tweets). This networking event's achieved high visibility and participation rate showcases a convincing example of how this social media platform can be used as a highly effective tool to host virtual Twitter-based international biomedical research events.

17 October 2024 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
AMAnshul Mishra
Anshul Mishra
ATAmandeep Thakur
Amandeep Thakur
RSRam Sharma
Ram Sharma
Raphael OnukuRaphael Onuku
Raphael Onuku
CKCharanjit Kaur
Charanjit Kaur
KNKunal Nepali
Kunal Nepali

14 July 2025 in Advanced Science
Verified
Journal Article
Open access
CSChih‐Jie Shen
Chih‐Jie Shen
HCHsien‐Chung Chen
Hsien‐Chung Chen
CLChien‐Liang Lin
Chien‐Liang Lin
ATAmandeep Thakur
Amandeep Thakur
Raphael OnukuRaphael Onuku
Raphael Onuku
THTsung-I Hsu
Tsung-I Hsu
Glioblastoma (GBM) is a highly aggressive brain tumor. Its poor prognosis is primarily due to recurrence and resistance to standard therapies, such as temozolomide (TMZ). Emerging evidence suggests that neuronal excitation within the tumor microenvironment contributes to the progression and chemoresistance of GBM. This study identifies prostaglandin E2 (PGE2) as a key regulator of neuronal activity that promotes tumor resistance. It is demonstrated that PGE2 activates neurons via the prostaglandin E1 (EP1) receptor, leading to intracellular calcium influx and phosphorylation of calcium/calmodulin dependent protein kinase II (CaMKII), which enhances synaptic plasticity. Neuronal excitation results in upregulation of synaptic proteins and neurotransmitter alterations, notably increasing glutamine and asparagine levels, which correlate with heightened chemoresistance. Co‐culture experiments confirmed that PGE2‐stimulated neurons induce resistance in adjacent GBM cells, highlighting a neuron‐tumor interaction that facilitates recurrence. To overcome this resistance mechanism, compound 11 is developed, a novel blood‐brain barrier (BBB)‐permeable celecoxib derivative that effectively inhibits PGE2 signaling. Treatment with compound 11 significantly reduces GBM growth, impairs neuronal excitation, and improves survival outcomes in preclinical models. These findings underscore PGE2‐induced neuronal excitation as a critical driver of drug resistance in GBM, and implicate compound 11 as a promising therapeutic agent to counteract PGE2‐driven tumor recurrence.

4 June 2022 in Tropical Journal of Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
Charles O. NnadiCharles O. Nnadi
Charles O. Nnadi
Raphael OnukuRaphael Onuku
Raphael Onuku
TAThecla O Ayoka
Thecla O Ayoka
NONdidiamaka H Okorie
Ndidiamaka H Okorie
NNNgozi J Nwodo
Ngozi J Nwodo
Purpose: To evaluate the in vitro activities of a gallic acid ester and two apigenin flavone glucoside constituents of Combretum dolichopetalum against Trypanosoma brucei brucei s427 (Tbs427) and Trypanosoma congolense IL3000 (Tc-IL3000), and their interactions with a lysosomal papain-like cysteine protease (CP) enzyme in silico.Methods: Anti-trypanosomal activity-guided separation of ethyl acetate fraction using column chromatographic (CC) technique and purification of the CC sub-fractions with semi-preparative HPLC yielded three (1-3) compounds. The structures were characterized based on nuclear magnetic resonance (NMR) spectroscopic analyses and tested for activities against Tbs427 and Tc-IL3000. All the compounds were subjected to molecular docking studies for the inhibition of trypanosomal cathepsin B (TbCatB) CP.Results: An ester (1), a butyl gallate, and two positional isomeric apigenin flavone glucosides (2, 3) were identified. The compounds 2 (vitexin) and 3 (isovitexin) showed low in vitro IC50 against the tested parasites. However, 2 (IC50, 25 μM) was more potent than 3 (IC50, 68 μM) against Tbs427 while both were equipotent (IC50 = 2, 11.5 μM and 3, 10.8 μM) against Tc-IL3000. Compound 1 (butyl gallate) showed higher activity against Tc-IL3000 (IC50 = 0.80 μM) than to Tbs427 (IC50, 2.72 μM). The molecular docking study showed that all the compounds had minimum binding energies with a higher affinity towards the active pocket of TbCatB compared to the controls and native inhibitor (CA074).Conclusion: The relatively high in vitro activities and their strong affinity for TbCatB support the need for further optimization of the compounds towards lead identification against animal trypanosomiasis.

14 September 2021 in Scientific African
Verified
Journal Article
Open access
AIA. Ibezim
A. Ibezim
Raphael OnukuRaphael Onuku
Raphael Onuku
FNF. Ntie-Kang
F. Ntie-Kang
NNN.J. Nwodo
N.J. Nwodo
MAM.U. Adikwu
M.U. Adikwu
Computational methods were used to filter two datasets (> 8,000 compounds) based on two criteria: higher binding affinity for MPRO than cocrystallized inhibitor and binding interactions with MPRO catalytic dyad (Cys145 and His41). After virtual screening involving ranking and reranking, eleven compounds were identified to satisfy these criteria and analysis of their structures revealed an unparallel common features among them which could be critical for their interactions with MPRO. However, only the topmost scoring compound (AV-203: Ki = 0.31 µM) exhibited relatively stable binding interaction during the period of 50 ns MD simulation and thus is a suitable template for drug development.

15 July 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MEMarlene Davis Ekpo
Marlene Davis Ekpo
JXJingxian Xie
Jingxian Xie
XLXiangjian Liu
Xiangjian Liu
Raphael OnukuRaphael Onuku
Raphael Onuku
GBGeorge Frimpong Boafo
George Frimpong Boafo
STSongwen Tan
Songwen Tan
Incorporating Cryopreservation Evaluations Into the Design of Cell-Based Drug Delivery Systems: An Opinion Paper